Trial Profile

A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2025 According to Bharat Biotech media release, The Phase2 HIV safety study is carried out by HIV Vaccine Trials Network (HVTN) and is funded by the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS).
09 Aug 2024 Planned End Date changed from 30 Nov 2024 to 2 Feb 2026.
09 Aug 2024 Planned primary completion date changed from 30 Nov 2024 to 2 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com